{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:48:33Z","timestamp":1792208913726,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Identify the most recent utility value estimates for cardiovascular disease (CVD) via systematic literature review (SLR) and explore trends in utility elicitation methods in the last 6\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This SLR was updated on January 25, 2018, and identified studies reporting utilities for myocardial infarction (MI), stroke, angina, peripheral artery disease (PAD), and any-cause revascularization by searching Embase, PubMed, Health Technology Assessment Database, and grey literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 375 studies reported CVD utilities (pre-2013 vs post-2013: MI, 38 vs 32; stroke, 86 vs 113; stable angina, 8 vs 9; undefined\/unstable angina, 23 vs 8; PAD, 29 vs 13; revascularization, 54 vs 40). Median average utilities for MI, stroke, and revascularization increased over time (pre-2013 vs post-2013: MI, 0.71 vs 0.79; stroke, 0.63 vs 0.64; revascularization, 0.76 vs 0.81); angina and PAD showed a decrease in median values over time (stable angina, 0.83 vs 0.72; undefined\/unstable angina, 0.70 vs 0.69; PAD, 0.76 vs 0.71). The proportion of utility estimates from trials increased across health states (pre-2013 vs post-2013: 22.5% vs 37.2%), as did the proportion of trials using the EuroQol Five Dimensions Questionnaire (EQ-5D; pre-2013 vs post-2013: 73.8% vs 91.4%). Use of methods such as the standard gamble, time trade-off, and Health Utilities Index has declined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Health state utilities for cardiovascular health states have changed in the last 6\u2009years, likely due to changes in the types of studies conducted, the patient populations evaluated, and possibly changing utility elicitation methods. The EQ-5D has been used more frequently.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12955-020-01407-y","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T12:02:47Z","timestamp":1595851367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-3946","authenticated-orcid":false,"given":"Marissa Blieden","family":"Betts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Rane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Bergrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit Kumar","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gulea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"1407_CR1","unstructured":"World Health Organization. Cardiovascular disease-WHO fact sheet. Published May 2017. https:\/\/www.who.int\/cardiovascular_diseases\/en\/. Accessed 20 Feb 2019."},{"key":"1407_CR2","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146\u2013603.","journal-title":"Circulation"},{"key":"1407_CR3","unstructured":"American Heart Association, American Stroke Association. Heart Disease and Stroke Statistics 2017 At-a-Glance. https:\/\/www.heart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/@smd\/documents\/downloadable\/ucm_491265.pdf. Accessed 6 May 2019."},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1\u201330.","journal-title":"J Health Econ"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1472-6963-11-75","volume":"11","author":"F Catala-Lopez","year":"2011","unstructured":"Catala-Lopez F, Garcia-Altes A, Alvarez-Martin E, G\u00e8nova-Maleras R, Morant-Ginestar C, Parada A. Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters? BMC Health Serv Res. 2011;11:75.","journal-title":"BMC Health Serv Res"},{"key":"1407_CR6","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Chapter 1 (introduction to economic evaluation) and chapter 2 (making decisions in health care). In: Drummond MF, editor. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005."},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/14737167.2017.1311210","volume":"17","author":"J Brown","year":"2017","unstructured":"Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, et al. Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling. Expert Rev Pharmacoecon Outcomes Res. 2017;17:153\u201364.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5\u201321.","journal-title":"Br Med Bull"},{"key":"1407_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12955-015-0266-9","volume":"13","author":"EW Davies","year":"2015","unstructured":"Davies EW, Matza LS, Worth G, Feeny DH, Kostelec J, Soroka S, et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health Qual Life Outcomes. 2015;13:90.","journal-title":"Health Qual Life Outcomes"},{"key":"1407_CR10","unstructured":"Phillips C. What is a QALY? http:\/\/www.bandolier.org.uk\/painres\/download\/whatis\/QALY.pdf. Accessed 18 Feb 2019."},{"key":"1407_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0021-9681(87)90019-1","volume":"40","author":"GW Torrance","year":"1987","unstructured":"Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40:593\u2013603.","journal-title":"J Chronic Dis"},{"key":"1407_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/14737167.2013.841545","volume":"13","author":"DW Smith","year":"2013","unstructured":"Smith DW, Davies EW, Wissinger E, Huelin R, Matza LS, Chung K. A systematic literature review of cardiovascular event utilities. Expert Rev Pharmacoecon Outcomes Res. 2013;13:767\u201390.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1407_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jval.2011.11.031","volume":"15","author":"E Heintz","year":"2012","unstructured":"Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health. 2012;15:475\u201384.","journal-title":"Value Health"},{"key":"1407_CR14","unstructured":"Sampson C. Generic Preference Based Measures: how economists measure health benefit. Adv Clin Neurosci Rehabil. 2013;13(5):23\u20134. https:\/\/www.acnr.co.uk\/wp-content\/uploads\/2013\/09\/rehab-sampson1.pdf."},{"key":"1407_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/02729890122062622","volume":"21","author":"GW Torrance","year":"2001","unstructured":"Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21:329\u201334.","journal-title":"Med Decis Making"},{"key":"1407_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28:172\u201391.","journal-title":"Eval Health Prof"},{"key":"1407_CR17","volume-title":"Assessing Quality of Life in Clinical Trials","author":"D Feeny","year":"2005","unstructured":"Feeny D. Preference-based measures: utility and quality-adjusted life years. In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials, vol. 2. 2nd ed. New York: Oxford University Press; 2005.","edition":"2"},{"key":"1407_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40273-015-0310-y","volume":"33","author":"T Peasgood","year":"2015","unstructured":"Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33:1101\u20135.","journal-title":"Pharmacoeconomics"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-8-13","volume":"8","author":"MT Dyer","year":"2010","unstructured":"Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8:13.","journal-title":"Health Qual Life Outcomes"},{"key":"1407_CR20","unstructured":"Ara R, Brazier J. HEDS Discussion Paper: Health related quality of life by age, gender and history of cardiovascular disease: results from the Health Survey for England. https:\/\/www.sheffield.ac.uk\/polopoly_fs\/1.43391!\/file\/HEDS-DP-09-12.pdf. Accessed 6 May 2019."},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13:509\u201318.","journal-title":"Value Health"},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"A51","DOI":"10.1016\/j.jval.2016.03.169","volume":"19","author":"M Blieden","year":"2016","unstructured":"Blieden M, Szatkowski A, Cheng L, Paoli CJ, Gandra SR. How do utilities vary for cardiovascular events? a systematic review. Value Health. 2016;19:A51.","journal-title":"Value Health"},{"key":"1407_CR23","unstructured":"National Health Service, National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. Published April 2004. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/191504\/NICE_guide_to_the_methods_of_technology_appraisal.pdf. Accessed 6 May 2019."},{"key":"1407_CR24","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Published April 2013. https:\/\/www.nice.org.uk\/guidance\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 6 May 2019."},{"key":"1407_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.vhri.2014.03.001","volume":"3","author":"T Kennedy-Martin","year":"2014","unstructured":"Kennedy-Martin T, Mitchell BD, Boye KS, Chen W, Curtis BH, Flynn JA, et al. The health technology assessment environment in mainland China, Japan, South Korea, and Taiwan\u2014implications for the evaluation of diabetes mellitus therapies. Value Health Reg Issues. 2014;3:108\u201316.","journal-title":"Value Health Reg Issues"},{"key":"1407_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/cer.12.20","volume":"1","author":"BM Yang","year":"2012","unstructured":"Yang BM. Interview: health technology assessment in Asia: an emerging trend. J Comp Eff Res. 2012;1:221\u20134.","journal-title":"J Comp Eff Res"},{"key":"1407_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/0272989X9701700212","volume":"17","author":"H Bleichrodt","year":"1997","unstructured":"Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating scale valuations. Med Decis Making. 1997;17:208\u201316.","journal-title":"Med Decis Making"},{"key":"1407_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/0272989X9801800213","volume":"18","author":"A Schwartz","year":"1998","unstructured":"Schwartz A. Rating scales in context. Med Decis Making. 1998;18:236.","journal-title":"Med Decis Making"},{"key":"1407_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/0272989X0102100103","volume":"21","author":"A Robinson","year":"2001","unstructured":"Robinson A, Loomes G, Jones-Lee M. Visual analog scales, standard gambles and relative risk aversion. Med Decis Making. 2001;21:17\u201327.","journal-title":"Med Decis Making"},{"key":"1407_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/ard.2006.060384","volume":"66","author":"A Boonen","year":"2007","unstructured":"Boonen A, van der Heijde D, Landewe R, van Tubergen A, Mielants H, Dougados M, et al. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum Dis. 2007;66:771\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1407_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873\u201384.","journal-title":"Health Econ"},{"key":"1407_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10198-005-0299-9","volume":"6","author":"S Bryan","year":"2005","unstructured":"Bryan S, Longworth L. Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ. 2005;6:253\u201360.","journal-title":"Eur J Health Econ"},{"key":"1407_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s11136-007-9237-x","volume":"16","author":"JP Grutters","year":"2007","unstructured":"Grutters JP, Joore MA, van der Horst F, Verschuure H, Dreschler WA, Anteunis LJC. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints. Qual Life Res. 2007;16:1439\u201349.","journal-title":"Qual Life Res"},{"key":"1407_CR34","first-page":"218","volume":"41","author":"S Macran","year":"2003","unstructured":"Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care. 2003;41:218\u201331.","journal-title":"Med Care"},{"key":"1407_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-4-20","volume":"4","author":"HF van Stel","year":"2006","unstructured":"van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4:20.","journal-title":"Health Qual Life Outcomes"},{"key":"1407_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1023\/A:1008952423122","volume":"8","author":"X Badia","year":"1999","unstructured":"Badia X, Monserrat S, Roset M, Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res. 1999;8:303\u201310.","journal-title":"Qual Life Res"},{"key":"1407_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hec.688","volume":"11","author":"H Bleichrodt","year":"2002","unstructured":"Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002;11:447\u201356.","journal-title":"Health Econ"},{"key":"1407_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0167-6296(96)00509-7","volume":"16","author":"H Bleichrodt","year":"1997","unstructured":"Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ. 1997;16:155\u201375.","journal-title":"J Health Econ"},{"key":"1407_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/0272989X06286480","volume":"26","author":"LM Lamers","year":"2006","unstructured":"Lamers LM, Stalmeier PF, Krabbe PF, Busschbach JJ. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making. 2006;26:173\u201381.","journal-title":"Med Decis Making"},{"key":"1407_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1017\/S0266462300161124","volume":"16","author":"AJ Martin","year":"2000","unstructured":"Martin AJ, Glasziou PP, Simes RJ, Lumley T. A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int J Technol Assess Health Care. 2000;16:137\u201347.","journal-title":"Int J Technol Assess Health Care"},{"key":"1407_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jclinepi.2007.03.001","volume":"60","author":"MA Puhan","year":"2007","unstructured":"Puhan MA, Schunemann HJ, Wong E, Griffith L, Guyatt GH. The standard gamble showed better construct validity than the time trade-off. J Clin Epidemiol. 2007;60:1029\u201333.","journal-title":"J Clin Epidemiol"},{"key":"1407_CR42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0277-9536(97)00057-9","volume":"45","author":"A Robinson","year":"1997","unstructured":"Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO: what lies behind the numbers? Soc Sci Med. 1997;45:1289\u201397.","journal-title":"Soc Sci Med"},{"key":"1407_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2796.1999.00535.x","volume":"246","author":"S Hallan","year":"1999","unstructured":"Hallan S, Asberg A, Indredavik B, Wideroe TE. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J Intern Med. 1999;246:549\u201359.","journal-title":"J Intern Med"},{"key":"1407_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/00005650-200001000-00013","volume":"38","author":"JA Johnson","year":"2000","unstructured":"Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38:115\u201321.","journal-title":"Med Care"},{"key":"1407_CR45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00134-004-2471-6","volume":"30","author":"A Kaarlola","year":"2004","unstructured":"Kaarlola A, Pettila V, Kekki P. Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Med. 2004;30:2245\u201352.","journal-title":"Intensive Care Med"},{"key":"1407_CR46","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/01.STR.28.10.1888","volume":"28","author":"SD Mathias","year":"1997","unstructured":"Mathias SD, Bates MM, Pasta DJ, Cisternas MG, Feeny D, Patrick DL. Use of the health utilities index with stroke patients and their caregivers. Stroke. 1997;28:1888\u201394.","journal-title":"Stroke."}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-020-01407-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T21:14:09Z","timestamp":1723324449000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-020-01407-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1186\/s12955-020-01407-y","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MBB, EB, MC, and CG (formerly) are employees of Evidera Inc., which received funding from Amgen Inc. to conduct this research. PR and YQ are employees of Amgen Inc. and own Amgen stock\/shares. GV is an employee of Amgen (Europe) GmbH and owns Amgen stock\/shares. MKB is an employee of BresMed Health Solutions, an independent consulting firm that received funding from Amgen Inc. to conduct the systematic literature review update.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}